Novartis receives third FDA approval for oral Fabhalta® (iptacopan) – the first and only treatment approved in C3 glomerulopathy (C3G) Fabhalta is the only oral alternative complement pathway ...

To receive the dial-in number, as well as your personalized PIN, you must register at the above link. Once registered, you will also have the option to have the system dial-out to you once the ...

Synergy CHC Corp. (NASDAQ: SNYR) (“Synergy” or the “Company”), a provider of consumer health care and lifestyle products, announced today that it plans to release financial results for the fourth ...

PRINCETON, N.J., March 20, 2025 (GLOBE NEWSWIRE) -- Teclison, Inc., a clinical-stage oncology company dedicated to advancing immunotherapeutic treatments for solid tumors, today announced that Ray Lee ...

MUSE Microscopy, Inc., a pioneer in digital pathology innovation, is proud to announce the development of its revolutionary slide-free, digital tissue imaging platform. This cutting-edge technology is ...

A registration statement on Form S-1 (File Number: 333-285935) relating to these securities was filed with the SEC on March 20, 2025, but has not yet become effective. These securities may not be sold ...

Amy joined Editas two and a half years ago as our head of Finance, working closely with the CFO. Her track record of financial decision-making, accounting acumen, and team leadership abilities make ...

The exercise price was DKK 224.40 per share for 7,917 of new shares and DKK 90.70 per share for 19,508 of new shares. The total proceeds to Zealand Pharma from the capital increase amount to DKK 3,545 ...

CAMBRIDGE, Mass., March 20, 2025 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage cell and genome engineering company, today reported financial results for the three-month period and full ...

Cash, cash equivalents and marketable securities of $358 million, expected to provide runway into 2028 ...

Under the agreement, Rhythm has agreed to repay $6.3 million in cash to RareStone. Rhythm also agreed to return all shares of RareStone that were acquired under the original agreement for no ...

MALVERN, Pa., March 20, 2025 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA Bio"), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions, today ...